Anastasios Konidaris
Directeur Financier/CFO chez AMNEAL PHARMACEUTICALS, INC.
Fortune : 4 M $ au 31/05/2024
Profil
Anastasios G.
Konidaris is currently the Director at Zep, Inc., Director at Kadmon Corp.
LLC, Executive VP, Chief Financial & Accounting Officer at Amneal Intermediate, Inc., and Chief Financial Officer & Executive Vice President at Amneal Pharmaceuticals, Inc. Formerly, he served as an Independent Director at Delcath Systems, Inc., Independent Director at Kadmon Holdings, Inc., Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc., Chief Financial Officer, Director & Executive VP at Alcresta Therapeutics, Inc., Group Vice President at Schering-Plough Corp., Chief Financial Officer & Senior Vice President at The Dun & Bradstreet Corp., CFO, Executive VP & Head-Corporate Development at Ikaria, Inc., and Vice President-Finance-North America at Pharmacia Corp.
Mr. Konidaris holds an MBA from Drexel University and an undergraduate degree from Gwynedd-Mercy College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/03/2024 | 527 316 ( 0,17% ) | 4 M $ | 31/05/2024 |
Postes actifs de Anastasios Konidaris
| Sociétés | Poste | Début |
|---|---|---|
| ZEP, INC. | Directeur/Membre du Conseil | 01/08/2015 |
| AMNEAL PHARMACEUTICALS, INC. | Directeur Financier/CFO | 07/11/2023 |
Kadmon Corp. LLC
 Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/01/2017 |
Amneal Intermediate, Inc.
 Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Directeur Financier/CFO | 12/03/2020 |
Anciens postes connus de Anastasios Konidaris
| Sociétés | Poste | Fin |
|---|---|---|
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Directeur Financier/CFO | 01/01/2020 |
| PERNIX THERAPEUTICS HOLDINGS INC | Directeur/Membre du Conseil | 15/11/2017 |
| IKARIA, INC. | Directeur Financier/CFO | 01/03/2015 |
| DELCATH SYSTEMS, INC. | Directeur/Membre du Conseil | 11/12/2014 |
| DUN & BRADSTREET CORP | Directeur Financier/CFO | 01/06/2011 |
Formation de Anastasios Konidaris
| Gwynedd-Mercy College | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DELCATH SYSTEMS, INC. | Health Technology |
| AMNEAL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
The Dun & Bradstreet Corp.
 The Dun & Bradstreet Corp. Data Processing ServicesTechnology Services The Dun & Bradstreet Corp. engages in the provision integrating data and insights services. It offers product to finance, sales and marketing, master data, supplier management, and compliance. The company was founded on July 20, 1841 and is headquartered in Short Hills, NJ. | Technology Services |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
Pernix Therapeutics Holdings, Inc.
 Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. It distributes products through the following brands: Treximet, Silenor, and Zohydro ER with BeadTek. The company was founded in 1996 and is headquartered in Morristown, NJ. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Zep, Inc.
 Zep, Inc. Chemicals: Major DiversifiedProcess Industries Zep, Inc. produces and markets cleaning and maintenance chemicals. It offers anti-bacterial and industrial hand care products, cleaners, degreasers, deodorizers, disinfectants, floor finishes, sanitizers, pest- and weed-control products and automotive maintenance chemicals. The firm market its products and services under the Zep, Zep Professional, Zep Commercial, Zep Automotive, and other Zep Inc. brands. The company was founded by Mandle Zaban, Sam Zaban, William Eplan, and Saul Powell in 1937 and is headquartered in Atlanta, GA. | Process Industries |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Amneal Intermediate, Inc.
Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
